Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2863-2871

  Sun, Ning L ^a   Zhu, Jun R ^b   Zhao, Yanxing ^c   Tu, Ying M ^d   Zhu, Jun Ren ^e   Cai, Nai Sheng ^e   Tang, Bin ^e   Sun, Ning Ling ^e   Wang, Hong Yi ^e   Hao, Yu Ming ^e   Wang, Bing Chen ^e   Yang, Kan ^e   Wang Jian Gang, G ^e   Hu, Jan ^e   Zhang, Zi Xin ^e   Huang, Lan ^e   Yu, Xue Jun ^e   Yang, Xin Chun ^e   Gao, Ming Ming ^e   Huang, Yan ^e   Li, Qiang ^e   Wan, Zheng ^e   Sun, Yue Min ^e   Su, Hai ^e   Xu, Jin Song ^e   He, Qing ^e   Wang, Fang ^e   Li, Zhan Quan ^e   Chen, Hong ^e   Liao, Yu Hao ^e   Zhou, Zi Hua ^e   Li, Hui ^e   Wang, Li Na ^e   Hong, Hua Shan ^e   Zhang, Lin Lin ^e   Peng, Yingxin ^e   Cao, Dong Ping ^e   Wang, Hai Chang ^e   He, Zheng ^e   Ma, Jian Lin ^e   Wu, Zhong ^e   Qu, Peng ^e   Li, Zhong Yan ^e   Huang, Zhen Wen ^e   Dong, Jing ^e   Lin, Jin Xiu ^e   Peng, Feng ^e   Yu, Bo ^e   Zhang, Shuo ^e   Jiang, Yi Nong ^e   Zhang, Ying ^e   Li, Wei Min ^e   Xu, Li Hua ^e   Han, Ya Ling ^e   Wang, Dong Mei ^e   Zhong, Guo Qiang ^e   Bi, Qi ^e   more..

^a PEKING UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Beijing SL Pharmaceutical Co Ltd   (China)

^e NONE

Author keywords

Chinese population; Combination therapy; Hydrochlorothiazide; Hypertension; Valsartan

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS VALSARTAN; PLACEBO; VALSARTAN;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHINA; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERURICEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CHINA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TIME FACTORS; VALINE;

EID: 55549136073     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802390647     Document Type: Article

References (31)

1. Fujita T, Wu Z, Park JB, et al. Briefings on JHS, CHS, KHS and THS guidelines and their difference from JNC VII and ESC/ESH. Int J Clin Pract 2006;60:3-6
2. Gu D, Reynolds K, Wu X, et al. InterASIA Collaborative Group. The International Collaborative Study of Cardiovascular Disease in ASIA. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension 2002; 40:920-7
3. Lawes CM, Rodgers A, Bennett DA, et al. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21: 707-16
4. He J, Klag MJ, Wu Z, et al. Stroke in the People's Republic of China. Stroke 1995;26:2222-7
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. J Am Med Assoc 2003;289:2560-72
6. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension [ESH-ESC Task Force on the Management of Arterial Hypertension]. J Hypertens 2007;25:1751-62
7. Shimamoto K, Fujita T, Wu Z, et al. Recommended optimal BP in the Asian population: difference from current JNC VII and ESC/ESH guidelines. Int J Clin Pract 2006;60:7-10
8. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study [Lisinopril-Hydrochlorothiazide group]. Arch Intern Med 1994;154:737-43
9. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002;4:343-9
10. Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002;162:1983-2005
11. Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001;14:286-92
12. Pool J, Oparil S, Hedner T, et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998;20:1106-14
13. Parving HH, Lehnert H, Mortensen BJ, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Eng J Med 2001;345:870-8
14. Brenner BM, Cooper ME, Zeeuw DD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Eng J Med 2001;345:861-9
15. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Amer Coll Cardiol 2002;40:1414-21
16. Hall WD. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Investig 1998;16:203-10
17. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003;12: 36-43
18. Joint National Committee. The sixth report of the joint National Committee on prevention, detection, evaluation and treatment of blood pressure. Arch Intern Med 1997;157: 2413-46.
19. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61-73
20. Ofili EO. Dispelling the myth of 'aggressive' antihypertensive therapy. J Clin Hypertens (Greenwich) 2006;8:4-11
21. Nash DT. Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics. Southern Med J 2007;100:386-92
22. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-62
23. He J, Go D, Wu X, et al. Major causes of death among men and women in China. New Engl J Med 2005;353;1124-34
24. Huang J, Wildmanb RP, Gua D, et al. Prevalence of isolated systolic and isolated diastolic hypertension subtypes in China. Am J Hypertens 2004;17:955-62
25. Aronow WS, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep 2004;6:124-9
26. Zanchetti A, Waeber B. Hypertension: which aspects of hypertension should we impact on and how. J Hypertens 2006;24:S2-S5
27. Ibrahim HR, Wenger NK. Secondary prevention of coronary heart disease in elderly patients. Am Fam Physician 2005; 71:2289-96
28. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [HOT Study Group]. Lancet 1998;351:1755-62
29. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991;265: 3255-64
30. Wang GJ, Staessen JA, Franklin SS. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005;45:907-13
31. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13